Is the business good?
How good a business is BLFS?
BioLife Solutions, Inc. earns 0.70% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
0.70%
Return on invested capital · cost of capital 9.0% · 8.3 points below what the capital costs: growth destroys value
- Operating margin
- 2.9%
Operating margin · Medical Instruments & Supplies median 5.8% · 12 months to Q2 2026
- Cash conversion
- 0.15×
Cash conversion · some of the reported profit has not turned into cash yet
- Share count, year on year
- +3.1%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | −13% |
| FY2021 | −30% |
| FY2022 | −7.8% |
| FY2023 | −25% |
| FY2024 | −6.0% |
| FY2025 | −17% |
Details›
- Operating margin12 months to Q2 2026
- 2.9%
- Net margin12 months to Q2 2026
- 56%
- Free cash flow margin
- 8.3%
- R&D as % of revenue
- 8.0%
- Revenue, trailing twelve months
- $103M
- Free cash flow, trailing twelve months
- $8.6M
- Net income, trailing twelve months
- $58M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 0.70%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Medical Instruments & Supplies
Ranks #2 of 27 by Smart Score